The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
Shying He
Advertisement
Articles by Shying He
Advertisement
Latest Updated Articles
China’s 2022 NRDL OutlookPublished: October 3rd 2022 | Updated: February 6th 2023
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
3
Leading in the Psychedelic Space: Q&A with Tarek Rabah
4
FDA Approves Hernexeos Under National Priority Voucher Program
5